Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
AXSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.11 - $139.13
Previous CloseN/A
Volume140.83K
Average Volume (3M)781.17K
Market Cap
$5.18B
Enterprise Value$3.99B
Total Cash (Recent Filing)-$2.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
May 05, 2025EPS Estimate
-1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding48,765,404
10 Day Avg. Volume742,743
30 Day Avg. Volume781,174
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.03
Price to Cash Flow (P/CF)-59.00
P/FCF Ratio254.00
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.34
Enterprise Value/Ebitda-14.55
Forecast
1Y Price Target
$175.87Price Target Upside65.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
---
Axsome Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Market PotentialVisible Alpha consensus sales for Auvelity are expected to grow to $1B by 2027.
Product PipelineAxsome's positive Phase III SYMPHONY trial of AXS-12 (reboxetine) in type NT1 will be presented as part of the clinical trial’s plenary session at the AAN meeting.
Sales GrowthAuvelity achieved 26K new patient starts in 4Q, bringing the total number of new patient starts since launch to 165K.
Bears Say
Clinical Study ConcernsDr. Maski would like to see more concrete improvements in excessive daytime sleepiness or mood benefits to use as monotherapy.
Investor FocusInvestor focus is primarily on Auvelity in depression and Alzheimer’s disease agitation, potentially overshadowing AXS-12.
Weekly Sales PerformanceAuvelity had an off week, with reported w/w TRx/NRx growth of -5%/-6%.
---
Ownership Overview
1.41% Insiders
19.89% Mutual Funds
1.64% Other Institutional Investors
63.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $64.11 and its highest was $139.13 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Axsome Therapeutics Inc’s market cap is $5.18B.
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is May 05, 2025 which is in 9 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Feb 18, 2025. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$0.539.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -1.32.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,765,404 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -2.333%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Currently, no hedge funds are holding shares in AXSM
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$175.87 (65.49% Upside)
$175.87 (65.49% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.58%
12-Months-Change
Fundamentals
Return on Equity
-231.63%
Trailing 12-Months
Asset Growth
-3.36%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
---
AXSM Company Deck
---
AXSM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Read More>---
AXSM Stock 12 Month Forecast
Average Price Target
$175.87
▲(65.49% Upside)
Technical Analysis
Cytokinetics
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Verona Pharma
―
Krystal Biotech
―
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+23.42%
reiterated a buy rating 24 days ago
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +23.42% per trade.
---